
	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Three Months Ended June 30, 2011
Total revenues
Third party	$	1,441,433	$	132,444	$	—		$	1,573,877
Intersegment		405		17,449		(17,854	)		—

Total	$	1,441,838	$	149,893	$	(17,854	)	$	1,573,877

Segment profitability	$	431,617	$	46,852	$	(197,998	)	$	280,471

	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Six Months Ended June 30, 2011
Total revenues
Third party	$	2,791,904	$	230,930	$	—		$	3,022,834
Intersegment		802		34,284		(35,086	)		—

Total	$	2,792,706	$	265,214	$	(35,086	)	$	3,022,834

Segment profitability	$	820,539	$	77,644	$	(406,038	)	$	492,145

	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Three Months Ended June 30, 2010
Total revenues
Third party	$	1,242,655	$	125,881	$	—		$	1,368,536
Intersegment		1,502		17,216		(18,718	)		—

Total	$	1,244,157	$	143,097	$	(18,718	)	$	1,368,536

Segment profitability	$	333,253	$	35,315	$	(173,982	)	$	194,586


	Generics Segment		Specialty Segment		Corporate / Other ⁽¹⁾			Consolidated
	(In thousands)
Six Months Ended June 30, 2010
Total revenues
Third party	$	2,450,516	$	210,393	$	—		$	2,660,909
Intersegment		31,921		33,730		(65,651	)		—

Total	$	2,482,437	$	244,123	$	(65,651	)	$	2,660,909

Segment profitability	$	658,587	$	55,119	$	(320,615	)	$	393,091

⁽¹⁾

Includes certain corporate general and administrative and research and development expenses; net charges for litigation settlements; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges, if any; and other expenses not directly attributable to segments.